(Q42017846)

English

In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis

scientific article published on 5 October 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 October 2017

In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis (English)

1 reference

Europe PubMed Central

15 October 2017

cystic fibrosis

0 references

0 references

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

Paula King

1

1 reference

Europe PubMed Central

15 October 2017

Olga Lomovskaya

2

1 reference

Europe PubMed Central

15 October 2017

David C Griffith

3

1 reference

Europe PubMed Central

15 October 2017

Jane L Burns

4

1 reference

Europe PubMed Central

15 October 2017

Michael N Dudley

5

1 reference

Europe PubMed Central

15 October 2017

language of work or name

0 references

publication date

5 October 2009

1 reference

Europe PubMed Central

15 October 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

15 October 2017

54

1 reference

Europe PubMed Central

15 October 2017

1

1 reference

Europe PubMed Central

15 October 2017

143-148

1 reference

Europe PubMed Central

15 October 2017

Aerosol antibiotics: considerations in pharmacological and clinical evaluation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

5 June 2018

Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

5 June 2018

Aminoglycoside antibiotics induce bacterial biofilm formation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

5 June 2018

Quinolones in 2005: an update.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

5 June 2018

Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

5 June 2018

Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

5 June 2018

A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

5 June 2018

Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

5 June 2018

In vitro antibacterial activity and pharmacodynamics of new quinolones

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

5 June 2018

Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

5 June 2018

High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

5 June 2018

Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

5 June 2018

Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

5 June 2018

In vitro and in vivo activities of levofloxacin against biofilm-producing Pseudomonas aeruginosa.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

5 June 2018

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

5 June 2018

Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

5 June 2018

Macromolecular mechanisms of sputum inhibition of tobramycin activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

5 June 2018

Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

17 August 2018

In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

17 August 2018

Antimicrobial susceptibility patterns of unusual nonfermentative gram-negative bacilli isolated from Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2002).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

17 August 2018

Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

17 August 2018

Comparison of in vitro susceptibilities to levofloxacin and ciprofloxacin with Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients in Northern Ireland.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

17 August 2018

Bacteriostatic and bactericidal activity of levofloxacin against clinical isolates from cystic fibrosis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

17 August 2018

Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

17 August 2018

High Rate of Macrolide Resistance inStaphylococcus aureusStrains from Patients with Cystic Fibrosis Reveals High Proportions of Hypermutable Strains

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

17 August 2018

Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with noncystic fibrosis isolates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

17 August 2018

Investigation into the selection frequency of resistant mutants and the bacterial kill rate by levofloxacin and ciprofloxacin in non-mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

17 August 2018

Emergence of new pathogens in CF: the devil we know or the devil we don't know?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

17 August 2018

Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

17 August 2018

Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2798504

17 August 2018

Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum

1 reference

https://pubmed.ncbi.nlm.nih.gov/19805554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19805554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro activity of ciprofloxacin, levofloxacin, and trovafloxacin, alone and in combination with beta-lactams, against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19805554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19805554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19805554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19805554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The changing epidemiology of cystic fibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19805554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.00248-09

1 reference

Europe PubMed Central

15 October 2017

release_jkd43npxgvhcrdb4fiqkh5oljy

1 reference

https://api.fatcat.wiki/v0/release/jkd43npxgvhcrdb4fiqkh5oljy

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

15 October 2017

1 reference

Europe PubMed Central

15 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42017846&oldid=2143963503"